Cross-Border Biotech—Amgen Completes Acquisition of Nuevolution

August 8, 2019

S&C represents Amgen, one of the world's largest biotechnology companies, with headquarters in the United States, in its previously announced public cash offer to acquire Nuevolution; the deal closed on July 29 and is valued at approximately $167 million. Founded in Copenhagen, Denmark, Nuevolution is a biopharmaceutical company that develops drug treatments for oncology and chronic inflammatory diseases. The combination of Amgen and Nuevolution will enable an integration of Nuevolution's technology and drug discovery expertise with Amgen's experience and capabilities in research and development, manufacturing and commercialization.

The S&C team advising Amgen on the offer was led by M&A partner Frank Aquila and includes special counsel Anca Mihaela Paraian and associates June Hu and Lisa Morales. S&C partners Renata Hesse (DC) and Michael Rosenthal (Brussels) advised on antitrust matters.